ArticleBlood advances2024

Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis.

Michael Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.